Optimizing lymphoDepletion to Improve Outcomes In Patients Receiving Cell Therapy With Yescarta
Status:
Recruiting
Trial end date:
2027-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1b study of participants with Diffuse Large B Cell Lymphoma (DLBCL). The
purpose of this study is to identify an optimized lymphodenpletion (LD) regimen by evaluating
standard and intermediate doses of Fludarabine (Flu) / Cyclophosphamide (Cy) with or without
a fixed dose of total lymphoid irradiation (TLI) in the setting of standard of care CAR T
cell therapy.